Carvedilol alleviates diabetic cardiomyopathy in diabetic rats

Zheng,Wencheng; Li,Ding; Gao,Xiang; Zhang,Wenqian; Robinson,Barry  O.

doi:10.3892/etm.2018.6954

Carvedilol alleviates diabetic cardiomyopathy in diabetic rats

Authors:
- Wencheng Zheng
- Ding Li
- Xiang Gao
- Wenqian Zhang
- Barry O. Robinson
View Affiliations

Affiliations: Fourth Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Cardiac Electrophysiology, Peking University People's Hospital, Peking University, Beijing 100044, P.R. China, First Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China, Department of Non‑Invasive Cardiovascular Services, Brookwood Health Hospital, Birmingham, AL 35211, USA
Published online on: November 12, 2018 https://doi.org/10.3892/etm.2018.6954
Pages: 479-487

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic cardiomyopathy (DCM) is characterized by structural and functional changes in the myocardium. Several studies have revealed that myocardial apoptosis and fibrosis occur during DCM. Studies have also indicated that oxidative stress may be a major factor associated with the development of DCM. Protein kinase C (PKC)β2 has been demonstrated to be activated in diabetic rats, and overexpression of PKCβ2 in the myocardium may result in cardiac hypertrophy and fibrosis. The P66shc adaptor protein, which is mediated by PKCβ, serves an important role in apoptosis during oxidative stress. The aim of the present study was to investigate whether the PKCβ2/P66shc oxidative stress pathway is associated with DCM, and to investigate the role and mechanisms of carvedilol in preserving cardiac function. Experimental diabetic rat models were induced by streptozotocin treatment accompanied by high energy intake. Carvedilol was orally administrated at a dose of 1 or 10 mg/kg/day. Cardiac function was evaluated by serum N‑terminal pro‑B‑type natriuretic peptide level and cardiac ultrasound. Myocardial inflammation, oxidative stress, apoptosis and fibrosis were assessed by histopathological and echocardiographic analyses and tests for oxidative markers. Associated proteins and factors were examined by immunohistochemical and western blot analyses. Rats in the diabetes mellitus group exhibited significantly decreased systolic cardiac function along with elevated expression levels of phosphorylated (p)‑PKCβ2, phos‑P66shc, caspase‑3, malondialdehyde, collagen type I, tumor necrosis factor‑α and interleukin‑1β, which were accompanied by disorder in metabolic processes. Treatment with carvedilol reversed these changes. Thus, the present results suggest that the PKCβ2/P66shc signaling pathway may be associated with diabetic cardiomyopathy; furthermore, carvedilol, as a novel β‑receptor blocker, may protect the myocardium from injury by suppressing the myocardial inflammatory response, fibrosis, P66shc‑mediated oxidative stress and subsequent apoptosis in myocardial tissue. Consequently, carvedilol may have potential as a therapy for the treatment of DCM.

View Figures

View References

1	Shaw JE, Sicree RA and Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bell DS: Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 26:2433–2441. 2003. View Article : Google Scholar : PubMed/NCBI
3	Fang ZY, Prins JB and Marwick TH: Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev. 25:543–567. 2004. View Article : Google Scholar : PubMed/NCBI
4	Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, Bader M, Schultheiss HP and Tschöpe C: Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes. 58:1373–1381. 2009. View Article : Google Scholar : PubMed/NCBI
5	Falcão-Pires I and Leite-Moreira AF: Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 17:325–344. 2012. View Article : Google Scholar : PubMed/NCBI
6	Aksakal E, Akaras N, Kurt M, Tanboga IH, Halici Z, Odabasoglu F, Bakirci EM and Unal B: The role of oxidative stress in diabetic cardiomyopathy: An experimental study. Eur Rev Med Pharmacol Sci. 15:1241–1246. 2011.PubMed/NCBI
7	Halliwell B: Biochemistry of oxidative stress. Biochem Soc Trans. 35:1147–1150. 2007. View Article : Google Scholar : PubMed/NCBI
8	Matés JM and Sánchez-Jiménez F: Antioxidant enzymes and their implications in pathophysiologic processes. Front Biosci. 4:D339–D345. 1999. View Article : Google Scholar : PubMed/NCBI
9	Mellor H and Parker P: The extended protein kinase C superfamily. Biochem J. 332:281–292. 1998. View Article : Google Scholar : PubMed/NCBI
10	Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M and Aizawa Y: Inactivation of 14-3-3 protein exacerbates cardiac hypertrophy and fibrosis through enhanced expression of protein kinase C beta 2 in experimental diabetes. Biol Pharm Bull. 28:957–962. 2005. View Article : Google Scholar : PubMed/NCBI
11	Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H and King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes. 51:2709–2718. 2002. View Article : Google Scholar : PubMed/NCBI
12	Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L and Pelicci PG: The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 402:309–313. 1999. View Article : Google Scholar : PubMed/NCBI
13	Nemoto S and Finkel T: Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science. 295:2450–2452. 2002. View Article : Google Scholar : PubMed/NCBI
14	Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieckowski MR, et al: Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science. 315:659–663. 2007. View Article : Google Scholar : PubMed/NCBI
15	Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, Lüscher TF and Cosentino F: Gene silencing of the mitochondrial adaptor p66shc suppresses vascular hyperglycemic memory in diabetes. Circ Res. 111:278–289. 2012. View Article : Google Scholar : PubMed/NCBI
16	Arab HH and El-Sawalhi MM: Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: Modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 268:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yasar A, Erdemir F, Parlaktas BS, Atilgan D, Koseoglu RD, Saylan O and Firat F: The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model. Kaohsiung J Med Sci. 29:19–25. 2013. View Article : Google Scholar : PubMed/NCBI
18	Feuerstein GZ, Poste G and Ruffolo RR Jr: Carvedilol update III: Rationale for and use in congestive heart failure. Drugs Today. 31:307–326. 1995. View Article : Google Scholar
19	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the care and use of laboratory animals. (Eighth). Publication no. 85-23(rev). 327:963–965. 1996.
20	Maeda H, Nagai H, Takemura G, Shintani-Ishida K, Komatsu M, Ogura S, Aki T, Shirai M, Kuwahira I and Yoshida K: Intermittent-hypoxia induced autophagy attenuates contractile dysfunction and myocardial injury in rat heart. Biochim Biophys Acta. 1832:1159–1166. 2013. View Article : Google Scholar : PubMed/NCBI
21	Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B and Anversa P: Myocardial cell death in human diabetes. Circ Res. 87:1123–1132. 2000. View Article : Google Scholar : PubMed/NCBI
22	Liu X, Li B, Wang W, Zhang C, Zhang M, Zhang Y, Xia Y, Dong Z, Guo Y and An F: Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis. Cardiovasc Drugs Ther. 26:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lei S, Li H, Xu J, Liu Y, Gao X, Wang J, Ng KF, Lau WB, Ma XL, Rodrigues B, et al: Hyperglycemia-induced protein kinase C β2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes. 62:2318–2328. 2013. View Article : Google Scholar : PubMed/NCBI
24	Huang H, Shan J, Pan XH, Wang HP and Qian LB: Carvedilol protected diabetic rat hearts via reducing oxidative stress. J Zhejiang Univ Sci B. 7:725–731. 2006. View Article : Google Scholar : PubMed/NCBI
25	Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD and Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol. 25:1225–1231. 1995. View Article : Google Scholar : PubMed/NCBI
26	Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM and Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1349–1355. 1996. View Article : Google Scholar : PubMed/NCBI
27	Tarquini R, Lazzeri C, Pala L, Rotella CM and Gensini GF: The diabetic cardiomyopathy. Acta Diabetol. 48:173–181. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, Meng FL, Deng YG and Wang RY: Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin. 32:999–1008. 2011. View Article : Google Scholar : PubMed/NCBI
29	Morsy MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA and Hassan MK: Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int. 2014:1052142014. View Article : Google Scholar : PubMed/NCBI
30	Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L, et al: Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 56:2115–2125. 2010. View Article : Google Scholar : PubMed/NCBI
31	Chen Z, Wang G, Zhai X, Hu Y, Gao D, Ma L, Yao J and Tian X: Selective inhibition of protein kinase C β2 attenuates the adaptor P66Shc-mediated intestinal ischemia-reperfusion injury. Cell Death Dis. 5:e11642014. View Article : Google Scholar : PubMed/NCBI
32	Clarke M and Dodson PM: PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab. 21:573–586. 2007. View Article : Google Scholar : PubMed/NCBI
33	Simpson PC: Beta-protein kinase C and hypertrophic signaling in human heart failure. Circulation. 99:334–337. 1999. View Article : Google Scholar : PubMed/NCBI
34	Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H and Gilbert RE: Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2:129–137. 2009. View Article : Google Scholar : PubMed/NCBI
35	Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER and Howard BV: Impact of diabetes on cardiac structure and function the strong heart study. Circulation. 101:2271–2276. 2000. View Article : Google Scholar : PubMed/NCBI